AbbVie Inc. $ABBV Shares Newly Bought by Sunesis Advisors LLC

Sunesis Advisors LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 9,159 shares of the company’s stock, valued at approximately $2,396,000. AbbVie accounts for approximately 1.2% of Sunesis Advisors LLC’s holdings, making the stock its 10th biggest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Westover Capital Advisors LLC raised its stake in AbbVie by 2.5% in the third quarter. Westover Capital Advisors LLC now owns 8,759 shares of the company’s stock worth $2,291,000 after buying an additional 210 shares in the last quarter. Peterson Wealth Services boosted its position in AbbVie by 5.0% during the 3rd quarter. Peterson Wealth Services now owns 15,285 shares of the company’s stock valued at $3,998,000 after acquiring an additional 728 shares in the last quarter. Leo Wealth LLC bought a new stake in AbbVie during the 3rd quarter valued at approximately $2,220,000. Apollon Wealth Management LLC boosted its position in AbbVie by 18.6% during the 3rd quarter. Apollon Wealth Management LLC now owns 145,103 shares of the company’s stock valued at $37,957,000 after acquiring an additional 22,722 shares in the last quarter. Finally, Holos Integrated Wealth LLC grew its holdings in shares of AbbVie by 22.5% during the 3rd quarter. Holos Integrated Wealth LLC now owns 1,107 shares of the company’s stock worth $313,000 after acquiring an additional 203 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
• Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
• Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
• Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
• Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
• Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and upped their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Finally, HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $279.86.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

AbbVie Price Performance

NYSE:ABBV opened at $286.88 on Tuesday. The firm has a market capitalization of $506.85 billion, a price-to-earnings ratio of 81.04, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a one year low of $190.75 and a one year high of $291.40. The business has a fifty day moving average price of $266.18 and a 200-day moving average price of $235.62.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.